HANSOH PHARMAC. HD-00001 (3KY) - Total Assets
Based on the latest financial reports, HANSOH PHARMAC. HD-00001 (3KY) holds total assets worth €39.90 Billion EUR (≈ $46.65 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how efficiently does HANSOH PHARMAC. HD-00001 generate cash for how efficiently the company converts equity into cash flow.
HANSOH PHARMAC. HD-00001 - Total Assets Trend (2021–2025)
This chart illustrates how HANSOH PHARMAC. HD-00001's total assets have evolved over time, based on quarterly financial data. See 3KY live share price for real-time trading data and today's change.
HANSOH PHARMAC. HD-00001 - Asset Composition Analysis
Current Asset Composition (December 2025)
HANSOH PHARMAC. HD-00001's total assets of €39.90 Billion consist of 89.1% current assets and 10.9% non-current assets. Explore 3KY net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 79.1% |
| Accounts Receivable | €3.04 Billion | 7.6% |
| Inventory | €608.92 Million | 1.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €362.65 Million | 0.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how HANSOH PHARMAC. HD-00001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HANSOH PHARMAC. HD-00001's current assets represent 89.1% of total assets in 2025, an increase from 85.3% in 2021.
- Cash Position: Cash and equivalents constituted 79.1% of total assets in 2025, up from 54.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 7.6% of total assets.
HANSOH PHARMAC. HD-00001 Competitors by Total Assets
Key competitors of HANSOH PHARMAC. HD-00001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangxi Synergy Pharmaceutical Co Ltd
SHE:300636
|
China | CN¥3.31 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $3.01 Million |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥11.38 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915
|
China | CN¥4.78 Billion |
HANSOH PHARMAC. HD-00001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.09 | 10.18 | 7.98 |
| Quick Ratio | 7.95 | 9.94 | 7.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €31.16 Billion | €24.75 Billion | €23.97 Billion |
HANSOH PHARMAC. HD-00001 - Advanced Valuation Insights
This section examines the relationship between HANSOH PHARMAC. HD-00001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.02 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | 26.0% |
| Total Assets | €39.90 Billion |
| Market Capitalization | $22.06 Billion USD |
Valuation Analysis
Below Book Valuation: The market values HANSOH PHARMAC. HD-00001's assets below their book value (0.55x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: HANSOH PHARMAC. HD-00001's assets grew by 26.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for HANSOH PHARMAC. HD-00001 (2021–2025)
The table below shows the annual total assets of HANSOH PHARMAC. HD-00001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €39.90 Billion ≈ $46.65 Billion |
+26.04% |
| 2024-12-31 | €31.66 Billion ≈ $37.01 Billion |
-4.18% |
| 2023-12-31 | €33.04 Billion ≈ $38.63 Billion |
+10.12% |
| 2022-12-31 | €30.00 Billion ≈ $35.08 Billion |
+10.46% |
| 2021-12-31 | €27.16 Billion ≈ $31.75 Billion |
-- |
About HANSOH PHARMAC. HD-00001
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products … Read more